Indium111 pentetreotide single photon emission computed tomography (In111 pentetreotide SPECT): A new technique to evaluate somatostatin receptors in chordomas

Stefano Di Girolamo, Fabrizio Ottaviani, Roberto Floris, Ernesto Bruno, Bianca Napolitano, Orazio Schillaci

Research output: Contribution to journalArticlepeer-review

Abstract

Chordomas are rare neoplasms originating along the neuraxis. Although they do not usually show cytological atypia, metastases have been reported in 30 per cent of cases. Survival rates in cases of skull base locations are low, and local recurrence is common after local excision. Radiation therapy is used in post-operative treatment and proton radiation therapy as the primary treatment. In the present paper we present the case of a 50-year-old Caucasian man affected by chordoma of the clivus, with liver and chest metastases, relapsed after several surgical local excisions, to discuss improvements in therapeutic and imaging techniques. Indium111 (In111) pentetreotide single photon emission computed tomography (SPECT) was employed to assess the presence of somatostatin receptors and to treat the tumour with radiolabelled Y 90-DOTA-lanreotide. Imaging, performed 2 months afterwards, showed stable disease in the lungs but a local progression in the metastases, in comparison with pre-treatment uptake. These data suggest the usefulness of radiolabelled somatostatin analogues in the diagnosis and therapy of chordomas.

Original languageEnglish
Pages (from-to)405-408
Number of pages4
JournalJournal of Laryngology and Otology
Volume119
Issue number5
DOIs
Publication statusPublished - May 2005

Keywords

  • Chordoma
  • Computed Tomography
  • Indium
  • Somatostatin

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Indium<sup>111</sup> pentetreotide single photon emission computed tomography (In<sup>111</sup> pentetreotide SPECT): A new technique to evaluate somatostatin receptors in chordomas'. Together they form a unique fingerprint.

Cite this